Biodegradable Poly(ε‐Caprolactone) Nanoparticles for Controlled Release of Malathion: Enhanced Bioefficacy and Reduced Phytotoxicity
Sign Up to like & getrecommendations! Published in 2025 at "Polymers for Advanced Technologies"
DOI: 10.1002/pat.70362
Abstract: The toxicity of pesticides can be minimized by encapsulating them in a controlled release system. Poly (ɛ‐caprolactone) nanoparticles (PCL NPs) loaded with malathion were synthesized, characterized, and evaluated for the controlled release and bioefficacy against… read more here.
Keywords: pcl nps; release; controlled release; bioefficacy ... See more keywords
Essential Oils Extracted from Boswellia sacra Oleo Gum Resin Loaded into PLGA–PCL Nanoparticles: Enhanced Cytotoxic and Apoptotic Effects against Breast Cancer Cells
Sign Up to like & getrecommendations! Published in 2022 at "ACS Omega"
DOI: 10.1021/acsomega.2c06390
Abstract: This work aims to develop and optimize blended polylactide-co-glycolide (PLGA) and poly(ε-caprolactone, PCL) loaded with Boswellia sacra oil (BO) to improve BO’s physicochemical properties and anti-breast cancer effects via enhancing apoptosis. In this context, BO… read more here.
Keywords: breast cancer; pcl; pcl nps; plga pcl ... See more keywords
Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Sign Up to like & getrecommendations! Published in 2018 at "Drug research"
DOI: 10.1055/a-0596-7288
Abstract: OBJECTIVE To enhance brain bioavailability for intranasally administered Eugenol-encapsulated-chitosan-coated-PCL-Nanoparticles (CS-EUG-PCL-NPs). METHODS Chitosan-coated-PCL-Nanoparticles (CS-PCL-NPs) were developed through double emulsification-solvent evaporation technique and further characterized for particle size, zeta potential, size distribution, encapsulation efficiency as well as… read more here.
Keywords: eug pcl; cerebral ischemia; drug; pcl nps ... See more keywords
Boosting Drug Discovery for Parkinson’s: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles
Sign Up to like & getrecommendations! Published in 2019 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics11070331
Abstract: The current pharmacological treatments for Parkinson’s disease only offer symptomatic relief to the patients and are based on the administration of levodopa and catechol-O-methyltransferase or monoamine oxidase-B inhibitors (IMAO-B). Since the majority of drug candidates… read more here.
Keywords: drug; pcl nps; drug discovery; monoamine oxidase ... See more keywords